extract: 2026-01-30-npr-kalshi-19-federal-lawsuits

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

entities/internet-finance/kalshi.md

@@ -45,7 +45,6 @@ CFTC-designated contract market for event-based trading. USD-denominated, KYC-re
 - **2025-XX-XX** — Positioned for retail adoption through traditional broker integration with native CFTC approval
 - **2026-02-19** — Tennessee federal court ruled in Kalshi's favor, finding sports contracts are 'swaps' under CEA exclusive jurisdiction and conflict preemption applies. Circuit split emerges as Nevada, Massachusetts, and Maryland courts rule against federal preemption.
 - **2026-02-19** — Tennessee federal court ruled in favor of Kalshi, holding that sports contracts are 'swaps' under CEA exclusive jurisdiction and conflict preemption applies because simultaneous compliance with federal and state requirements is impossible
-- **2026-01-30** — NPR reports Kalshi faces 19 federal lawsuits across three categories: 8 state/tribal offensive suits, 6 Kalshi offensive suits against state regulators, and 5 consumer class actions alleging illegal gambling service worsening addiction
 ## Competitive Position
 - **Regulation-first**: Only CFTC-designated prediction market exchange. Institutional credibility.
 - **vs Polymarket**: Different market — Kalshi targets mainstream/institutional users who won't touch crypto. Polymarket targets crypto-native users who want permissionless market creation. Both grew massively post-2024 election.

inbox/archive/.extraction-debug/2026-01-01-frontiers-social-prescribing-health-economics-systematic-review.json

@@ -1,24 +0,0 @@
-{
-  "rejected_claims": [
-    {
-      "filename": "social-prescribing-produces-social-value-but-not-healthcare-cost-savings.md",
-      "issues": [
-        "missing_attribution_extractor"
-      ]
-    }
-  ],
-  "validation_stats": {
-    "total": 1,
-    "kept": 0,
-    "fixed": 1,
-    "rejected": 1,
-    "fixes_applied": [
-      "social-prescribing-produces-social-value-but-not-healthcare-cost-savings.md:set_created:2026-03-18"
-    ],
-    "rejections": [
-      "social-prescribing-produces-social-value-but-not-healthcare-cost-savings.md:missing_attribution_extractor"
-    ]
-  },
-  "model": "anthropic/claude-sonnet-4.5",
-  "date": "2026-03-18"
-}

inbox/archive/2026-01-01-frontiers-social-prescribing-health-economics-systematic-review.md

@@ -7,14 +7,10 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: paper
-status: null-result
+status: unprocessed
 priority: medium
 triage_tag: claim
 tags: [social-prescribing, health-economics, cost-effectiveness, evidence-quality, international-health-systems]
-processed_by: vida
-processed_date: 2026-03-18
-extraction_model: "anthropic/claude-sonnet-4.5"
-extraction_notes: "LLM returned 1 claims, 1 rejected by validator"
 ---
 
 ## Content
@@ -55,15 +51,3 @@ Complementary evidence on healthcare utilization (from separate reviews):
 ## Curator Notes
 PRIMARY CONNECTION: social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem
 WHY ARCHIVED: Provides the economic evidence (or lack thereof) for social prescribing, the most scaled non-clinical health intervention globally. The SROI/financial ROI divergence is a key finding for understanding which behavioral health interventions can scale under healthcare payment models.
-
-
-## Key Facts
-- Social prescribing systematic review included 18 studies: 5 RCTs, 1 quasi-experimental, 12 mixed-methods
-- Geographic coverage: England, Wales, Ireland, Europe, Australia, New Zealand, Canada, USA
-- Intervention types: exercise/loneliness prevention (n=10), coaching (n=3), nature-based (n=3), dance/movement (n=2)
-- SROI ratios ranged from £1.17 to £7.08 per £1 invested
-- Financial ROI ranged from 0.11 to 0.43 per £1 invested
-- 28% average reduction in GP demand (range: 2-70%)
-- 24% average reduction in A&E attendance (range: 8-27%)
-- 15 of 17 utilization studies were uncontrolled before-and-after designs
-- Mean attrition rate across studies: 38%